UNSPSC 51102905: Amodiaquine and pyrimethamine/sulfadoxine

This is a combination therapy used for seasonal malaria chemoprevention. The first component, AMODIAQUINE, has a US FDA Unique Ingredient Identifier of 220236ED28. The second component, PYRIMETHAMINE, has a US FDA Unique Ingredient Identifier of Z3614QOX8W. The third component, SULFADOXINE, has a US FDA Unique Ingredient Identifier of 88463U4SM5.

UNSPSC 51102905 Amodiaquine and pyrimethamine/sulfadoxine (Commodity) shows minimal recent activity in state and local procurement aligned with its nominal scope. The eight opportunities posted between April and October 2026 span pharmaceutical services, emergency medical supplies, drug deactivation systems, forensic reference materials, and a group purchasing organization membership—none of which involve amodiaquine or pyrimethamine/sulfadoxine specifically. The Collier County single-source notice (PUR20975, posted October 8, 2026, protest deadline September 24, 2026) addresses a mobile application for EMS drug-dosage calculation (Handtevy), entirely unrelated to the antimalarial drugs this code designates. Similarly, Dane County's RFP 2026RFP061PR (posted September 30, 2026, due October 22, 2026) solicits comprehensive pharmaceutical services for a long-term care facility with no mention of the specific therapeutics under this code. West Texas Centers for Mental Health and Mental Retardation's RFP RX1001 (posted August 10, 2026, due August 21, 2026) covers psychiatric and general medications across 35 service sites but does not isolate amodiaquine or pyrimethamine/sulfadoxine. The City of Tucson Fire Department's RFP 260217 (posted August 13, 2026, due June 24, 2026) focuses on basic and advanced life support pharmaceuticals and vending machines, and Pinellas County's forensic drug standards ITQ 26-0305-ITQ (posted April 23, 2026) procures certified reference materials for toxicology and drug analysis—neither targeting antimalarial treatment regimens.

Issuing bodies include county health systems, municipal fire and police departments, regional mental health authorities, and county forensic laboratories across Florida, Wisconsin, Arizona, Oregon, Texas, the District of Columbia, and Kentucky. Pharmacological procurement under related codes appears fragmented across long-term care, emergency medical services, mental health, and forensic applications, with no standout repeat buyer and no indication of state-level bulk antimalarial purchasing. Geographic activity spans multiple states without concentration. This code does not currently reflect active state or local procurement of amodiaquine or pyrimethamine/sulfadoxine; the mismatch between the code's therapeutic scope and actual solicitation content suggests misclassification by issuing bodies or a genuine absence of state and local demand for these specific antimalarial agents in the recent period.